Imagine a global **23andMe**, but with a broader focus on clinical diagnostics and preventative health solutions.

Think of it as a next-generation **LabCorp** or **Quest Diagnostics**, emphasizing direct-to-consumer genetic testing and personalized health management.

• CircleDNA: A direct-to-consumer comprehensive DNA test providing personalized insights into health, ancestry, diet, and fitness.
• ACT Genomics: A precision oncology service offering comprehensive genomic profiling for cancer diagnosis, prognosis, and treatment guidance.
• Rutgers: Clinical diagnostic testing services, encompassing general laboratory diagnostics and historically, large-scale COVID-19 testing.

Prenetics Global (PRE) sells its products and services to both other companies and directly to individuals. While the company is expanding its business-to-business (B2B) offerings, particularly in cancer diagnostics with ACT Genomics and Insighta, its direct-to-consumer brands like CircleDNA and the strategic focus on the Circle Health Pod for the general public indicate a significant, if not primary, emphasis on serving individuals.

Therefore, we will describe the categories of individual customers that Prenetics Global serves:

Categories of Individual Customers:

• Health-Conscious Individuals Seeking Personalized Wellness Insights: This category includes customers who utilize products such as CircleDNA and DNAfit to gain genetic insights into areas like diet, exercise response, stress management, and sleep patterns. They aim to optimize their lifestyle choices based on their unique genetic makeup for improved overall well-being.
• Proactive Health Managers Seeking Comprehensive Health Risk Assessments: These individuals are interested in more extensive genetic screenings to understand their predispositions to various health conditions (e.g., certain cancers, cardiovascular diseases), carrier status for hereditary conditions, and pharmacogenomic insights (how they might react to certain medications). They use this information for proactive health management and early detection strategies.
• Individuals Seeking Convenient and Accessible Diagnostic Testing: This category encompasses users of the Circle Health Pods and other accessible diagnostic services who seek convenient, on-demand health testing outside traditional clinical settings. They may use these services for routine health monitoring, quick checks of key biomarkers, or initial health assessments for preventive care.

• Illumina, Inc. (ILMN)
• Thermo Fisher Scientific Inc. (TMO)

Danny Yeung, Co-Founder & Chief Executive Officer

Mr. Yeung has served as the Co-Founder and Chief Executive Officer of Prenetics since its inception in 2014. He is a serial entrepreneur, having founded uBuyiBuy in 2010, which was acquired by Groupon within six months. He then served as CEO of Groupon East Asia, scaling it to be the largest e-commerce company in the region with over US$130 million in annual revenue. His entrepreneurial journey began at age 25, franchising the Hong Kong dessert chain "Hui Lau Shan" into the USA, and later venturing into a hospitality furniture business, both of which he exited. Prior to Prenetics, Mr. Yeung was a Founding Partner at SXE Ventures, leading investments in genetic testing companies and in Honey Science, which was acquired by PayPal for US$4 billion in 2019. In 2023, he launched Insighta, a joint venture focused on multi-cancer early detection, backed by Prenetics and later Tencent. He also co-founded IM8, a health and wellness brand, with David Beckham.

Stephen Lo, Chief Financial Officer

Mr. Lo has served as the Chief Financial Officer of Prenetics since 2018, overseeing financial operations, corporate accounting and reporting, treasury, financial and tax planning and analysis, and investor relations. Prior to joining Prenetics, Mr. Lo was a Vice President in the Asia Pacific Investment Banking team of Citigroup from 2014 to 2018, where he worked on initial public offering transactions, placements, debt issuances, and cross-border mergers and acquisitions in Asia and the U.S. From 2007 to 2011, he was an auditor with Ernst & Young. He holds an MBA from Yale University, an MSc from the London School of Economics, and a bachelor's degree from Hong Kong Baptist University. Mr. Lo is a Fellow of the Hong Kong Institute of Certified Public Accountants, a Chartered Accountant of the ICAEW, and a CFA Charterholder.

Dr. Lawrence Tzang, Ph.D., Co-Founder & Chief Scientific Officer

Dr. Tzang is a Co-Founder of Prenetics and has served as its Chief Scientific Officer since its founding in 2014. He is responsible for overseeing the development, evaluation, and implementation of new testing products and services. His role also includes the supervision of laboratory setup and operation, and the governance of medical laboratory accreditation.

Avi Lasarow, Chief Executive Officer (Europe, Middle East and Africa)

Mr. Lasarow is the Chief Executive Officer for Europe, Middle East, and Africa at Prenetics, where he is responsible for international market growth in these regions. He is recognized as an award-winning pioneer in lifestyle genetics. Mr. Lasarow began his career at Citibank before transitioning to found several successful life sciences companies. He also served as the youngest ever Honorary Consul for South Africa.

David Vanderveen, Executive Director, President of Americas

Mr. Vanderveen serves as an Executive Director and President of Americas for Prenetics. He has a 30-year track record in the beverage, nutrition, and technology sectors, leading disruptive change in both private and public companies. Most recently, from 2022, he served as CEO of Nirvana Water Sciences, where he built a team to transform the brand, product portfolio, and go-to-market strategy.

The clear emerging threat to Prenetics Global (PRE) is the rise of comprehensive, AI-driven, and continuously monitored personal health operating systems or platforms. These platforms aim to integrate an individual's complete health profile—including genomic data, real-time biometric data from wearables, blood markers, microbiome insights, and lifestyle data—to provide dynamic, actionable, and personalized health interventions and preventive strategies. This represents a potential paradigm shift from PRE's current model, which largely focuses on providing diagnostic snapshots (e.g., DNA tests, blood tests) to a system that offers continuous, integrated, and AI-driven health management. If a major technology company (e.g., Apple, Google) or a well-funded startup successfully launches such a holistic and effective "Personal Health OS," it could significantly diminish the value proposition of PRE's diagnostic-centric services by offering a more comprehensive, proactive, and continuously adaptive approach to health and wellness.

Prenetics Global (PRE) operates in several addressable markets for its main products and services:

• IM8 (Health and Longevity Brand/Supplements): The total addressable market for IM8 and related health and wellness products is estimated to be over $700 billion globally. This market is experiencing growth across various regions, including the U.S., Canada, Europe, the Middle East, Southeast Asia, Singapore, and Hong Kong. IM8 itself has achieved global reach with customer purchases across 31 countries.
• CircleDNA (Direct-to-Consumer DNA Tests/Consumer Genetic Testing) and Insighta (DNA Testing for Major Diseases and Cancers): These services fall within the broader genomics market and the cancer diagnostics market.
  • The global genomics market is valued at approximately USD 46.06 billion in 2025 and is projected to reach USD 186.64 billion by 2035.
  • The global cancer diagnostics market is estimated to be between USD 115 billion and USD 116 billion in 2025, with projections to reach up to USD 199.54 billion by 2034.
  • In the United States, cancer diagnostics revenue was USD 41.47 billion in 2024 and is expected to grow to USD 59.53 billion by 2030. The Asia-Pacific region is anticipated to be the fastest-growing market for cancer diagnostics.

1. Rapid Growth and Expansion of IM8: Prenetics' flagship premium health and longevity brand, IM8, is positioned as the primary catalyst for future revenue growth. IM8 has demonstrated exceptional growth, reaching significant annualized recurring revenue (ARR) milestones rapidly, with projections to reach between $180 million and $200 million in revenue for fiscal year 2026, targeting $300 million ARR by the end of 2026. This growth is driven by strong market demand for its health and wellness products, including its "Daily Ultimate Essentials" supplement.
2. International Market Expansion: Prenetics is actively pursuing continued international expansion for its IM8 brand. IM8 has already achieved global reach with hundreds of thousands of customer purchases across over 30 countries, and international markets represent a significant portion of its revenue, indicating a clear strategy to broaden its geographical footprint.
3. New Product Innovations within IM8: The company plans to introduce new product innovations to further drive IM8's revenue growth. This focus on expanding the product portfolio within its high-growth health and longevity segment is expected to capture additional market share and cater to evolving consumer needs.
4. Strategic Focus and Divestiture of Non-Core Assets: Prenetics has undergone a strategic shift, divesting non-core business units such as ACT Genomics, and is conducting a strategic review of other non-core assets like Europa Sports Partners, CircleDNA, and Insighta. This allows the company to concentrate its resources and capital on IM8, which is identified as its highest-growth and highest-margin business unit, thereby maximizing returns and accelerating overall revenue growth.
5. Enhanced Marketing Initiatives and Brand Partnerships: Leveraging high-profile brand partnerships, such as those with co-founder David Beckham and global ambassador Aryna Sabalenka, is a key component of Prenetics' growth strategy for IM8. The company also intends to implement enhanced marketing initiatives across various sports and wellness verticals to boost brand visibility, attract new customers, and solidify IM8's position in the competitive health landscape.

Share Repurchases

• On November 30, 2022, Prenetics Global's board authorized a share repurchase program for up to $20 million, to be executed over a 24-month period.
• As of April 24, 2024, the company had repurchased 542,444 shares for $2.36 million under the authorized program.
• The repurchase program aimed to deliver long-term shareholder value, particularly as shares were trading below the company's net book value.

Share Issuance

• Prenetics completed a public offering on October 28, 2025, selling 2,722,642 Class A ordinary shares and associated warrants, raising approximately $44.0 million in gross proceeds.
• The proceeds from this offering are designated for the global expansion of its IM8 brand and the strategic accumulation of Bitcoin.
• The public offering was oversubscribed and featured a double warrant structure.

Inbound Investments

• The October 2025 equity offering attracted a distinguished group of strategic investors, including Kraken, Exodus, XtalPi, DL Holdings, GPTX by Jihan Wu, and saw increased stakes from existing investors such as Aryna Sabalenka and Adrian Cheng.
• In 2024, Prenetics sold a portion of its stake in Insighta to Tencent, generating $30 million in cash and valuing its remaining stake at $70 million.

Outbound Investments

• Approximately six months prior to March 5, 2025, Prenetics acquired Europa, a sports distribution company, to support the growth of its IM8 brand.
• The company is strategically accumulating Bitcoin, with holdings reaching 275 BTC as of October 27, 2025, and approximately 387 BTC (valued at ~ $40 million) by November 10, 2025.
• Prenetics has divested assets from its clinical business units to sharpen its focus on the consumer business, including a $72 million divestiture of ACT Genomics and the partial sale of its stake in Insighta.

Capital Expenditures

• Information on specific dollar amounts for capital expenditures is not explicitly available in the provided search results.